What's in Liquidia Technologies, Inc.'s pipeline?

Liquidia Technologies, Inc. has 6 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with Liquidia Technologies, Inc.'s portfolio?

Top competitors by shared drug class: AOP Orphan Pharmaceuticals AG, Civi Biopharma, Inc., GlaxoSmithKline, Ludwig-Maximilians - University of Munich, Lung Biotechnology PBC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/liquidia-technologies-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

Liquidia Technologies, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liquidia Technologies, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
L606	L606	phase 3	Prostacyclin analog	Prostacyclin receptor (IP receptor)	Pulmonary Hypertension
LIQ861 Inhaled Treprostinil	LIQ861 Inhaled Treprostinil	phase 3	Prostacyclin analog	Prostacyclin receptor (IP receptor)	Cardiovascular / Pulmonary Hypertension

Therapeutic area mix

Cardiovascular / Pulmonary Hypertension · 1
Pulmonary Hypertension · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AOP Orphan Pharmaceuticals AG · 1 shared drug class
Civi Biopharma, Inc. · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Ludwig-Maximilians - University of Munich · 1 shared drug class
Lung Biotechnology PBC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Liquidia Technologies, Inc.:

Cite this brief

Drug Landscape (2026). Liquidia Technologies, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/liquidia-technologies-inc. Accessed 2026-06-09.